Similar articles

• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Raal FJ, et al. Lancet. 2010 Mar 20;375(9719):998-1006. doi: 10.1016/S0140-6736(10)60284-X. Lancet. 2010. PMID: 20227758 Clinical Trial.
• Lipid-lowering treatment for homozygous familial hypercholesterolaemia.

  Santos RD. Santos RD. Lancet. 2013 Apr 6;381(9873):1182. doi: 10.1016/S0140-6736(13)60797-7. Lancet. 2013. PMID: 23561997 No abstract available.
• Trial watch: Antisense agent reduces LDL-cholesterol levels in high-risk patients.

  [No authors listed] [No authors listed] Nat Rev Drug Discov. 2010 Jan;9(1):10. doi: 10.1038/nrd3093. Nat Rev Drug Discov. 2010. PMID: 20043021 No abstract available.
• Mipomersen, an antisense apolipoprotein B synthesis inhibitor.

  Bell DA, Hooper AJ, Burnett JR. Bell DA, et al. Expert Opin Investig Drugs. 2011 Feb;20(2):265-72. doi: 10.1517/13543784.2011.547471. Epub 2011 Jan 6. Expert Opin Investig Drugs. 2011. PMID: 21210756 Review.
• The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

  Agarwala A, Jones P, Nambi V. Agarwala A, et al. Curr Atheroscler Rep. 2015 Jan;17(1):467. doi: 10.1007/s11883-014-0467-4. Curr Atheroscler Rep. 2015. PMID: 25398643 Review.